ReviewCancers2020
Transcription Factors in Cancer Development and Therapy.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.
- Pooled it
- ZNF695 Promotes Colorectal Cancer Progression Through Transcriptional Activation of CBX8 and Subsequent Wnt/β-Catenin Signaling Activation.Molecular carcinogenesis · 2026Article
- Impact of Socioeconomic Status on Early Gastric Cancer Outcomes and Treatment Disparity: a SEER analysis.Journal of gastrointestinal cancer · 2026Article
- IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma.Blood · 2026Article
- The MYB-related transcription factor MYPOP acts as a selective regulator of cancer cell growth.Communications biology · 2026Article
- Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance.Journal of experimental & clinical cancer research : CR · 2026Review
- Multi-omics and bulk sequencing analyses reveal the roles of prognosis and immune aspects of super-enhancer-induced ZBED2 in pan-cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- POU6F1 Expression Predicts Favorable Prognosis in Lung Adenocarcinoma: Validation Using Patient Cohort and TCGA Data.Current issues in molecular biology · 2026Article
- Glucocorticoid-Induced Proteome and Phosphoproteome Changes in Breast Cancer Cell Lines.Journal of proteome research · 2026Article
- S100A13 transcriptionally activated by SP1 facilitates osteosarcoma metastasis.Discover oncology · 2026Article
- ZNF711 promotes enzalutamide resistance through transcriptional and epigenetic modification of the androgen receptor signaling pathway.Cellular and molecular life sciences : CMLS · 2026Article
- Transcription-based comparison ofMicrobiology spectrum · 2026Article
- E2F1 K117 methylation by SETD6 disrupts BRD4-E2F1 binding and modulates E2F1 chromatin binding and gene regulation in prostate cancer cells.Nucleic acids research · 2026Article
- Development and Validation of a Prognostic Signature Based on Transcription Factors Associated with Endoplasmic Reticulum Stress in Pancreatic Adenocarcinoma.Current medicinal chemistry · 2026Article
- Unraveling the molecular landscape of pancreatic cancer: a systems biology approach to identify therapeutic targets.Discover oncology · 2025Article
- Platelet-activating factor induces ferroptosis by binding to ATF3 and inhibiting the SLC7A11/GPX4 axis to suppress the progression of endometrial carcinoma.Biology direct · 2025Article
- Article
- Interplay Between Type 2 Diabetes Susceptibility and Prostate Cancer Progression: Functional Insights intoDiagnostics (Basel, Switzerland) · 2025Article
- Machine learning on transcription factor expression profiles for precision breast cancer therapy.Cancer cell international · 2025Article
- Cell-free DNA-based inference of the activities of 370 + transcription factors mirrors their activities in tumors.BMC genomics · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cancer is a multi-step process and requires constitutive expression/activation of transcription factors (TFs) for growth and survival. Many of the TFs reported so far are critical for carcinogenesis. These include pro-inflammatory TFs, hypoxia-inducible factors (HIFs), cell proliferation and epithelial-mesenchymal transition (EMT)-controlling TFs, pluripotency TFs upregulated in cancer stem-like cells, and the nuclear receptors (NRs). Some of those, including HIFs, Myc, ETS-1, and β-catenin, are multifunctional and may regulate multiple other TFs involved in various pro-oncogenic events, including proliferation, survival, metabolism, invasion, and metastasis. High expression of some TFs is also correlated with poor prognosis and chemoresistance, constituting a significant challenge in cancer treatment. Considering the pivotal role of TFs in cancer, there is an urgent need to develop strategies targeting them. Targeting TFs, in combination with other chemotherapeutics, could emerge as a better strategy to target cancer. So far, targeting NRs have shown promising results in improving survival. In this review, we provide a comprehensive overview of the TFs that play a central role in cancer progression, which could be potential therapeutic candidates for developing specific inhibitors. Here, we also discuss the efforts made to target some of those TFs, including NRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.